- Bob Herman
- Sep 25
The 20 top-selling prescription drugs
Humira, the blockbuster anti-inflammatory drug that is routinely blasted on TV commercials, netted $13.6 billion in gross U.S. sales last year — the most of any brand-name prescription drug. The 20 top-selling drugs generated more than $98 billion in gross U.S. sales in 2016, or about $20 billion more than the U.S. Department of Transportation's budget from last year.
Data: QuintilesIMS Institute; Chart: Chris Canipe / Axios
The bottom line: The biggest drug sellers, which are heavily advertised on TV, treat conditions that affect millions of Americans. But the growth in pharmaceutical spending continues to be well above inflation, putting many people in a bind when they pick up their medicine at the pharmacy.
The data: QuintilesIMS, a pharmaceutical research firm, collected the data in an annual report. The totals are gross figures, so they do not factor in rebates and discounts that are negotiated with insurers and pharmacy benefit managers, nor do they include coupons and promotions.
Rebates between drug manufacturers and middlemen are not public information. But here's some context: Humira netted $13.6 billion in gross U.S. revenue. AbbVie, the company that makes Humira, reported $10.4 billion in net U.S. sales for the drug in its audited financials. That indicates rebates and discounts for Humira could have been around 25%.
- AbbVie told analysts at Leerink Partners that peak global revenue for the drug will hit $20 billion before biosimilar versions hit the market in 2022 and eat into sales. The company also believes the Trump administration won't do anything to affect drug pricing decisions.
- Hepatitis C drug Harvoni has busted onto the scene. The drug, made by Gilead Sciences, brought in $10 billion of gross sales in 2016 and has sparked debate over how much a drug should cost if it cures a disease.
- The drug with the fifth-highest sales was Remicade, made by Johnson & Johnson. Pfizer is suing Johnson & Johnson, alleging the company has blocked Pfizer's cheaper biosimilar version of Remicade from penetrating the market.